{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:53Z","timestamp":1786982753918,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Not Applicable","award":["000"],"award-info":[{"award-number":["000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40263-016-0334-7","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T04:37:00Z","timestamp":1461559020000},"page":"405-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Vanessa C.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnoush","family":"Alamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi N.","family":"Yatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"issue":"9","key":"334_CR1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1176\/ajp.2006.163.9.1561","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry. 2006;163(9):1561\u20138.","journal-title":"Am J Psychiatry"},{"key":"334_CR2","volume-title":"2004 update","author":"The global burden of disease","year":"2008","unstructured":"The global burden of disease. 2004 update. Geneva: World Health Organization; 2008."},{"key":"334_CR3","first-page":"21","volume":"420","author":"J Alonso","year":"2004","unstructured":"Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21\u20137.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"1","key":"334_CR4","first-page":"9","volume":"18","author":"H Gilmour","year":"2007","unstructured":"Gilmour H, Patten SB. Depression and work impairment. Health Rep. 2007;18(1):9\u201322.","journal-title":"Health Rep"},{"key":"334_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-244X-9-78","volume":"9","author":"RW Lam","year":"2009","unstructured":"Lam RW, Michalak EE, Yatham LN. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. BMC Psychiatry. 2009;9:78.","journal-title":"BMC Psychiatry"},{"issue":"10","key":"334_CR6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archpsyc.1992.01820100005001","volume":"49","author":"J Mintz","year":"1992","unstructured":"Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 1992;49(10):761\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"334_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/da.20580","volume":"27","author":"HG Birnbaum","year":"2010","unstructured":"Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78\u201389.","journal-title":"Depress Anxiety"},{"issue":"1","key":"334_CR8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/appi.ajp.163.1.148","volume":"163","author":"M Zimmerman","year":"2006","unstructured":"Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D. How should remission from depression be defined? The depressed patient\u2019s perspective. Am J Psychiatry. 2006;163(1):148\u201350.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"334_CR9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005053-198808000-00003","volume":"176","author":"MB Keller","year":"1988","unstructured":"Keller MB, Lavori PW. The adequacy of treating depression. J Nerv Ment Dis. 1988;176(8):471\u20134.","journal-title":"J Nerv Ment Dis"},{"issue":"3","key":"334_CR10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cpr.2009.01.005","volume":"29","author":"PE McKnight","year":"2009","unstructured":"McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243\u201359.","journal-title":"Clin Psychol Rev"},{"issue":"4","key":"334_CR11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00023210-200519040-00004","volume":"19","author":"P Bech","year":"2005","unstructured":"Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19(4):313\u201324.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"334_CR12","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jad.2011.03.046","volume":"132","author":"RW Lam","year":"2011","unstructured":"Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(Suppl 1):S9\u201313.","journal-title":"J Affect Disord"},{"issue":"10","key":"334_CR13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4088\/JCP.v69n1001","volume":"69","author":"AJ Gelenberg","year":"2008","unstructured":"Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008;69(10):1513\u201328.","journal-title":"J Clin Psychiatry"},{"issue":"23","key":"334_CR14","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1001\/jama.289.23.3152","volume":"289","author":"MB Keller","year":"2003","unstructured":"Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289(23):3152\u201360.","journal-title":"JAMA"},{"issue":"4","key":"334_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4088\/JCP.v61n0405","volume":"61","author":"RM Hirschfeld","year":"2000","unstructured":"Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Moller HJ, et al. Social functioning in depression: a review. J Clin Psychiatry. 2000;61(4):268\u201375.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"334_CR16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.psychres.2005.05.016","volume":"141","author":"M Zimmerman","year":"2006","unstructured":"Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: implications for how remission from depression should be defined. Psychiatry Res. 2006;141(2):185\u201391.","journal-title":"Psychiatry Res"},{"issue":"2","key":"334_CR17","doi-asserted-by":"crossref","first-page":"e90311","DOI":"10.1371\/journal.pone.0090311","volume":"9","author":"EI Fried","year":"2014","unstructured":"Fried EI, Nesse RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One. 2014;9(2):e90311.","journal-title":"PLoS One"},{"issue":"12","key":"334_CR18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/070674371105601206","volume":"56","author":"CS Dewa","year":"2011","unstructured":"Dewa CS, Thompson AH, Jacobs P. The association of treatment of depressive episodes and work productivity. Can J Psychiatry. 2011;56(12):743\u201350.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"334_CR19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11530230-000000000-00000","volume":"24","author":"TL Greer","year":"2010","unstructured":"Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24(4):267\u201384.","journal-title":"CNS Drugs"},{"issue":"3","key":"334_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/YIC.0b013e3283277614","volume":"24","author":"MH Trivedi","year":"2009","unstructured":"Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol. 2009;24(3):133\u20138.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"334_CR21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0165-0327(88)90060-2","volume":"14","author":"E Giller","year":"1988","unstructured":"Giller E, Bialos D, Riddle MA, Waldo MC. MAOI treatment response: multiaxial assessment. J Affect Disord. 1988;14(2):171\u20135.","journal-title":"J Affect Disord"},{"issue":"9","key":"334_CR22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpsyc.1976.01770090101010","volume":"33","author":"MM Weissman","year":"1976","unstructured":"Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry. 1976;33(9):1111\u20135.","journal-title":"Arch Gen Psychiatry"},{"key":"334_CR23","volume-title":"Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV)","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994."},{"key":"334_CR24","volume-title":"10th rev","author":"International classification of diseases","year":"1992","unstructured":"International classification of diseases. 10th rev. Geneva: WHO; 1992."},{"key":"334_CR25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2288-7-40","volume":"7","author":"L Bax","year":"2007","unstructured":"Bax L, Yu LM, Ikeda N, Moons KG. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methodol. 2007;7:40.","journal-title":"BMC Med Res Methodol"},{"key":"334_CR26","unstructured":"Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011; cited April 10, 2015]. The Cochrane Collaboration; 2011. http:\/\/www.cochrane-handbook.org ."},{"issue":"2","key":"334_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0b013e3181d420a7","volume":"30","author":"J Zajecka","year":"2010","unstructured":"Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30(2):135\u201344.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"334_CR28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0269881109106953","volume":"24","author":"K Hewett","year":"2010","unstructured":"Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2010;24(8):1209\u201316.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"334_CR29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0269881108089602","volume":"23","author":"K Hewett","year":"2009","unstructured":"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2009;23(5):531\u20138.","journal-title":"J Psychopharmacol"},{"key":"334_CR30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-244X-13-94","volume":"13","author":"MR Liebowitz","year":"2013","unstructured":"Liebowitz MR, Tourian KA, Hwang E. Mele L; Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50\u00a0mg\/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013;13:94.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"334_CR31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.pra.0000426323.59698.64","volume":"19","author":"N Iwata","year":"2013","unstructured":"Iwata N, Tourian KA, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 50\u00a0mg\/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013;19(1):5\u201314.","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"334_CR32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","volume":"31","author":"BW Dunlop","year":"2011","unstructured":"Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569\u201376.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"334_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YIC.0b013e32830cebed","volume":"23","author":"P Boyer","year":"2008","unstructured":"Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100\u00a0mg\/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243\u201353.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"334_CR34","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1185\/03007990802161923","volume":"24","author":"MR Liebowitz","year":"2008","unstructured":"Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50\u00a0mg\/day and 100\u00a0mg\/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877\u201390.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"334_CR35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4088\/JCP.v68n0504","volume":"68","author":"NA DeMartinis","year":"2007","unstructured":"DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677\u201388.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"334_CR36","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4088\/JCP.v68n1105","volume":"68","author":"MR Liebowitz","year":"2007","unstructured":"Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663\u201372.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"334_CR37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hup.1262","volume":"27","author":"TM Oakes","year":"2012","unstructured":"Oakes TM, Myers AL, Marangell LB, Ahl J, Prakash A, Thase ME, et al. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol. 2012;27(1):47\u201356.","journal-title":"Hum Psychopharmacol"},{"issue":"10","key":"334_CR38","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1185\/03007995.2011.609539","volume":"27","author":"PJ Gaynor","year":"2011","unstructured":"Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr Med Res Opin. 2011;27(10):1849\u201358.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"334_CR39","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/03007995.2011.609540","volume":"27","author":"PJ Gaynor","year":"2011","unstructured":"Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Curr Med Res Opin. 2011;27(10):1859\u201367.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"334_CR40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","volume":"23","author":"AA Nierenberg","year":"2007","unstructured":"Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007;23(2):401\u201316.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"334_CR41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","volume":"21","author":"DG Perahia","year":"2006","unstructured":"Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry. 2006;21(6):367\u201378.","journal-title":"Eur Psychiatry"},{"issue":"6","key":"334_CR42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","volume":"14","author":"MJ Detke","year":"2004","unstructured":"Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14(6):457\u201370.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"334_CR43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1503\/jpn.130040","volume":"39","author":"D Bakish","year":"2014","unstructured":"Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, et al. Levomilnacipran ER 40\u00a0mg and 80\u00a0mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39(1):40\u20139.","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"334_CR44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/YIC.0000000000000009","volume":"29","author":"SA Montgomery","year":"2014","unstructured":"Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2014;29(1):26\u201335.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"334_CR45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4088\/JCP.12m08197","volume":"74","author":"GM Asnis","year":"2013","unstructured":"Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg W. Efficacy and safety of levomilnacipran sustained release 40\u00a0mg, 80\u00a0mg, or 120\u00a0mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(3):242\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"334_CR46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","volume":"29","author":"JP Boulenger","year":"2014","unstructured":"Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20\u00a0mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138\u201349.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"334_CR47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4088\/JCP.14m09337","volume":"76","author":"AR Mahableshwarkar","year":"2015","unstructured":"Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015;76(5):583\u201391.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"334_CR48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"SA Montgomery","year":"2014","unstructured":"Montgomery SA, Nielsen RZ, Poulsen LH, Haggstrom L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin -noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470\u2013782.","journal-title":"Hum Psychopharmacol"},{"issue":"1\u20132","key":"334_CR49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.psychres.2014.06.053","volume":"220","author":"JK Soczynska","year":"2014","unstructured":"Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, et al. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res. 2014;220(1\u20132):245\u201350.","journal-title":"Psychiatry Res"},{"issue":"7","key":"334_CR50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1185\/030079907X210732","volume":"23","author":"A Wade","year":"2007","unstructured":"Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007;23(7):1605\u201314.","journal-title":"Curr Med Res Opin"},{"issue":"1 pt 2","key":"334_CR51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00019053-199813010-00015","volume":"13","author":"P Boyer","year":"1998","unstructured":"Boyer P, Danion JM, Bisserbe JC, Hotton JM, Troy S. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics. 1998;13(1 pt 2):157\u201369.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"334_CR52","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4088\/JCP.v66n1015","volume":"66","author":"A Sir","year":"2005","unstructured":"Sir A, D\u2019Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66(10):1312\u201320.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"334_CR53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004850-200207000-00003","volume":"17","author":"C Gorenstein","year":"2002","unstructured":"Gorenstein C, Andrade L, Moreno RA, Artes R. Social adjustment in depressed patients treated with venlafaxine and amitriptyline. Int Clin Psychopharmacol. 2002;17(4):171\u20135.","journal-title":"Int Clin Psychopharmacol"},{"key":"334_CR54","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000."},{"key":"334_CR55","first-page":"151","volume-title":"The anxiety disease","author":"DS Sheehan","year":"1983","unstructured":"Sheehan DS. The anxiety disease. New York: Charles Scribner & Sons; 1983. p. 151."},{"issue":"2","key":"334_CR56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","volume":"23","author":"KH Sheehan","year":"2008","unstructured":"Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan disability scale. Int Clin Psychopharmacol. 2008;23(2):70\u201383.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"334_CR57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2190\/T8EM-C8YH-373N-1UWD","volume":"27","author":"AC Leon","year":"1997","unstructured":"Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan disability scale. Int J Psychiatry Med. 1997;27(2):93\u2013105.","journal-title":"Int J Psychiatry Med"},{"issue":"1","key":"334_CR58","first-page":"13","volume":"33","author":"J Endicott","year":"1997","unstructured":"Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull. 1997;33(1):13\u20136.","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"334_CR59","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"334_CR60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00005650-200101000-00009","volume":"39","author":"D Lerner","year":"2001","unstructured":"Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care. 2001;39(1):72\u201385.","journal-title":"Med Care"},{"issue":"3","key":"334_CR61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02602324","volume":"1","author":"AM Jette","year":"1986","unstructured":"Jette AM, Davies AR, Cleary PD, Calkins DR, Rubenstein LV, Fink A, et al. The functional status questionnaire: reliability and validity when used in primary care. J Gen Intern Med. 1986;1(3):143\u20139.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"334_CR62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2190\/GP4F-WQK9-WRHY-7JM9","volume":"25","author":"PR Yarnold","year":"1995","unstructured":"Yarnold PR, Stille FC, Martin GJ. Cross-sectional psychometric assessment of the functional status questionnaire: use with geriatric versus nongeriatric ambulatory medical patients. Int J Psychiatry Med. 1995;25(4):305\u201317.","journal-title":"Int J Psychiatry Med"},{"issue":"10","key":"334_CR63","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4088\/JCP.09m05133blu","volume":"70","author":"CN Soares","year":"2009","unstructured":"Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry. 2009;70(10):1365\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"334_CR64","first-page":"298","volume":"27","author":"M Mancini","year":"2012","unstructured":"Mancini M, Sheehan DV, Demyttenaere K, Amore M, Deberdt W, Quail D, et al. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. Int Clin Psychopharmacol. 2012;27(6):298\u2013309.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"334_CR65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0000000000000033","volume":"29","author":"A Sambunaris","year":"2014","unstructured":"Sambunaris A, Gommoll C, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014;29(4):197\u2013205.","journal-title":"Int Clin Psychopharmacol"},{"key":"334_CR66","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"334_CR67","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511761676","volume-title":"The essential guide to effect sizes: an introduction to statistical power, meta-analysis and the interpretation of research results","author":"PD Ellis","year":"2010","unstructured":"Ellis PD. The essential guide to effect sizes: an introduction to statistical power, meta-analysis and the interpretation of research results. Cambridge: Cambridge University Press; 2010."},{"issue":"4","key":"334_CR68","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archpsyc.57.4.375","volume":"57","author":"LL Judd","year":"2000","unstructured":"Judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon AC, Maser JD, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57(4):375\u201380.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"334_CR69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jad.2007.06.014","volume":"108","author":"LL Judd","year":"2008","unstructured":"Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord. 2008;108(1\u20132):49\u201358.","journal-title":"J Affect Disord"},{"issue":"2","key":"334_CR70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0006-3223(01)01291-4","volume":"51","author":"RM Hirschfeld","year":"2002","unstructured":"Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry. 2002;51(2):123\u201333.","journal-title":"Biol Psychiatry"},{"issue":"1\u20132","key":"334_CR71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1399-5618.2007.00326.x","volume":"9","author":"N Kennedy","year":"2007","unstructured":"Kennedy N, Foy K, Sherazi R, McDonough M, McKeon P. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007;9(1\u20132):25\u201337.","journal-title":"Bipolar Disord"},{"issue":"11","key":"334_CR72","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/JOM.0b013e3181f475cc","volume":"52","author":"A Brooks","year":"2010","unstructured":"Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW. Presenteeism: critical issues. J Occup Environ Med. 2010;52(11):1055\u201367.","journal-title":"J Occup Environ Med"},{"issue":"8","key":"334_CR73","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/JOM.0b013e3181ec7cd3","volume":"52","author":"K Nieuwenhuijsen","year":"2010","unstructured":"Nieuwenhuijsen K, Franche RL, van Dijk FJ. Work functioning measurement: tools for occupational mental health research. J Occup Environ Med. 2010;52(8):778\u201390.","journal-title":"J Occup Environ Med"},{"issue":"8","key":"334_CR74","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jval.2012.08.2206","volume":"15","author":"N Despi\u00e9gel","year":"2012","unstructured":"Despi\u00e9gel N, Danchenko N, Fran\u00e7ois C, Lensberg B, Drummond MF. The use and performance of productivity scales to evaluate presenteeism in mood disorders. Value Health. 2012;15(8):1148\u201361.","journal-title":"Value Health"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0334-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0334-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0334-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:27Z","timestamp":1559490087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0334-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0334-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,25]]}}}